BRIEF-Kazia Therapeutics Provides Update On Paxalisib Regulatory Pathway Following Type C Meeting With FDA

Reuters
31 Dec 2024
BRIEF-<a href="https://laohu8.com/S/KZA.AU">Kazia Therapeutics</a> Provides Update On Paxalisib Regulatory Pathway Following Type C Meeting With FDA

Dec 31 (Reuters) - Kazia Therapeutics Ltd KZIA.O:

  • KAZIA THERAPEUTICS PROVIDES UPDATE ON PAXALISIB REGULATORY PATHWAY FOLLOWING TYPE C MEETING WITH FDA

  • KAZIA THERAPEUTICS LTD - FDA SAYS OS DATA NOT APPROPRIATE FOR ACCELERATED APPROVAL

  • KAZIA THERAPEUTICS LTD - FDA COMMENTS OS DATA SUPPORTIVE FOR PIVOTAL REGISTRATIONAL STUDY

  • KAZIA THERAPEUTICS LTD - ALIGNS WITH FDA ON PHASE 3 STUDY DESIGN

Source text: ID:nPn5mLr4Da

Further company coverage: KZIA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10